Holen Sie sich die Stockscreener-App
0.4903
11.02%
-0.0607
Handel nachbörslich:
.47
-0.0203
-4.14%
Schlusskurs vom Vortag:
$0.551
Offen:
$0.5146
24-Stunden-Volumen:
239.08K
Relative Volume:
0.17
Marktkapitalisierung:
$2.48M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-5.71%
1M Leistung:
+23.38%
6M Leistung:
-16.03%
1J Leistung:
-77.71%
1-Tages-Spanne:
$0.4669
$0.53
1-Wochen-Bereich:
$0.4669
$0.69
52-Wochen-Spanne:
$0.185
$2.29
Entero Therapeutics Inc Stock (ENTO) Company Profile
Firmenname
Entero Therapeutics Inc
Sektor
Branche
Telefon
561-589-7020
Adresse
777 YAMATO ROAD, BOCA RATON
Vergleichen Sie ENTO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ENTO
Entero Therapeutics Inc
|
0.4903 | 2.48M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Entero Therapeutics Inc Aktie (ENTO) Neueste Nachrichten
More than 1 million power banks recalled after some consumers report fires - The Globe and Mail
FluroTech Ltd. Announces Change in Directors - TradingView
Thinkific Announces Closing of Secondary Offering of Approximately C$14.5 Million of Rhino Group's Shares - The Globe and Mail
Entero Therapeutics names Richard Paolone interim CEO - MSN
Celiac Disease Market Analysis 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Statistics, Revenue, Prevalence, Medication, Treatment Market and Companies by DelveInsight - The Globe and Mail
Layoff Tracker: Capsida Downsizes as Part of Shift to Clinical-Stage Company - BioSpace
Entero Therapeutics IncNow Offering 15.2 Million Shares Of Common Stock - marketscreener.com
Public market insider buying at Goldshore Resources (GSHR) - The Globe and Mail
Pre-market Movers: NIVF, TRAW, KKR, AGEN... - RTTNews
Cattle Strength Pushes Triple Digit Gains at Midday - The Globe and Mail
Why UiPath Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket - Benzinga
Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews
NuCana Stock Price, Quotes and Forecasts | NASDAQ:NCNA - Benzinga
Polyrizon Stock Price, Quotes and Forecasts | NASDAQ:PLRZ - Benzinga
Biodexa Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:BDRX - Benzinga
Pre-market Movers: NRXS, EYEN, TIL, HCTI, EKSO... - RTTNews
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Pre-market Movers: CMRX, CPIX, PBM, CRVO... - RTTNews
Entero Therapeutics, Inc. SEC 10-Q Report - TradingView
Entero Therapeutics Inc Subsidiary Immunogenx Enters Settlement Agreement - marketscreener.com
Entero Therapeutics Finalizes Settlement with Mattress Liquidators - TipRanks
Entero (ENTO) Announces Public Offering of 16.67 Million Shares - GuruFocus
Pre-market Movers: CNSP, XLO, PLRZ, SGMO... - RTTNews
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Entero Therapeutics faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com South Africa
Entero Therapeutics faces Nasdaq delisting over equity shortfall - Investing.com
Titan Environmental Solutions Inc. Appoints Edward J. Borkowski and Edward F. Feighan to its Board of Directors - The Manila Times
Strategic Board Shake-Up: Ex-Pharma CFO and Former Congressman Join Titan Environmental's Expansion Push - Stock Titan
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket - Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders - ACCESS Newswire
Entero Therapeutics Delays 10-K Filing - TipRanks
Celiac Disease Pipeline: Pioneering Progress with 25+ Leading - openPR.com
VOO ETF News, 4/1/2025 - The Globe and Mail
Tesla Inc. (TSLA) Stock Analysis & Analyst Coverage Update - The Globe and Mail
Entero Therapeutics Enters Rescission Deal to Unwind Merger With ImmunogenX - MarketScreener
Entero Therapeutics slips 7%, signs rescission agreement with ImmunogenX - MSN
Strategic Shift: Entero Therapeutics Unwinds Recent Merger and Strengthens Leadership - Stock Titan
Entero Therapeutics Announces Signing of Rescission Agreement with ImmunogenX, LLC - Yahoo Finance
Micron (MU) Stock Trades Down, Here Is Why - The Globe and Mail
Johnson & Johnson plans $55 billion in US investments over the next four years - The Globe and Mail
Hogs Close with Weakness on Thursday - The Globe and Mail
With outlook uncertain, the Bank of England joins the US Fed in putting interest rates on hold - The Globe and Mail
This Under-the-Radar AI Stock Could Be 1 of the Best Buys for a Recession - The Globe and Mail
Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days - The Globe and Mail
European ETFs Gain Momentum as Global Markets Shift - The Globe and Mail
The Unpleasant Truth: The Stock Market Is Still Historically Pricey, Even With the Nasdaq and S&P 500 Recently Falling Into Correction Territory - The Globe and Mail
Celiac Disease Market Expected to Experience Major Growth - openPR
Finanzdaten der Entero Therapeutics Inc-Aktie (ENTO)
Es liegen keine Finanzdaten für Entero Therapeutics Inc (ENTO) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.91%
1.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):